Badania kliniczne w obszarze: nieswoiste zapalenia jelit, prowadzone w ośrodkach w mieście Rzeszów. Zobacz też wszystkie badania: nieswoiste zapalenia jelit w Polsce.
35 badań: 34 rekrutują, 1 wkrótce zacznie.
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
+8Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
+30A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
+26A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
+23Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
+9A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
+20A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
+20An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
+33A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
+31A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
+33An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
+34A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
+31Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
+15Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
+14Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
+8A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
+33A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
+13A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
+6A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
+15A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
+12Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
+4A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
+8Assessment of the safety and effectiveness of vedolizumab induction therapy compared to standard infliximab therapy in pediatric patients with ulcerative colitis "VEDI-UC”
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
+5A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
+17A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
+9A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
+9A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
+9Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.